GRAIL reported a 28% increase in total revenue to $40.8 million for Q1 2026, driven by a 37% rise in Galleri test revenue and a 50% increase in test volume to over 56,000. The company plans to integrate its Galleri cancer detection test into Epic's electronic health record platform to expand nationwide access by the end of 2026. Despite a net loss of $93.2 million, GRAIL improved its financial performance compared to last year and will present new clinical data at the 2026 ASCO Annual Meeting. This integration and ongoing clinical validation aim to boost adoption and early cancer detection capabilities.
Dogecoin's net position delta is increasing despite price consolidation near recent lows, indicating accumulation by investors. A significant drop in profitable holders suggests a potential market bottom, supported by a TD Sequential buy signal point...
Bitcoin has recovered above $62,000 after defending the $58,000 support level twice, signaling a strong buying zone. This rebound was driven by a combination of easing inflation fears, a short squeeze, and a structural shift as European traders move ...
Bitcoin investors currently hold an average unrealized loss of about 20%, with the True Market Mean (TMM) cost basis near $76,700 acting as a key resistance level. This TMM reflects the average acquisition cost of active holders, excluding dormant co...
XRP climbed above $1.14 driven by positive ETF inflows, increased wallet activity, and technical buy signals, signaling renewed accumulation despite ongoing US regulatory uncertainty. Institutional demand remains strong with $6.55 million inflows int...
Wall Street analysts maintain a cautious optimism on Rivian Automotive, assigning it a consensus 'Moderate Buy' rating despite a modest expected price change. Sixteen analysts show mixed opinions with eight buys, five holds, and three sells, and a 12...
